MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Начало・Списък с акции・Insulet Corp

Insulet Corp

Затворен

СекторЗдравеопазване

289.09 -2.78

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

289.03

Максимум

297.4

Ключови измерители
By Trading Economics
Приходи	-65M 35M
Продажби	-29M 569M
P/E Средно за сектора	54.376 39.564
Марж на печалбата	6.221
Служители	3,900
EBITDA	-53M 89M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+14.23% upside

Дивиденти
By Dow Jones
Следващи печалби	7.08.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.5B 21B
Предишно отваряне	291.87
Предишно затваряне	289.09

Настроения в новините

By Acuity

92%

2 / 376 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

252.29 / 259.38 Подкрепа & съпротива

Insulet Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.07.2025 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

FCC Approves U.S. Cellular Sale to T-Mobile

11.07.2025 г., 17:28 ч. UTC

Значими двигатели на пазара

SharpLink Gaming Gains on Ethereum Purchase

11.07.2025 г., 16:57 ч. UTC

Печалби

BASF Cuts Outlook on Global Economy Uncertainty

11.07.2025 г., 21:45 ч. UTC

Пазарно говорене

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11.07.2025 г., 19:46 ч. UTC

Придобивния, сливания и поглъщания

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11.07.2025 г., 19:45 ч. UTC

Пазарно говорене

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11.07.2025 г., 19:05 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11.07.2025 г., 18:18 ч. UTC

Пазарно говорене

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11.07.2025 г., 17:35 ч. UTC

Пазарно говорене

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11.07.2025 г., 17:26 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11.07.2025 г., 16:53 ч. UTC

Пазарно говорене

Crude Futures Add to Early Gains -- Market Talk

11.07.2025 г., 16:42 ч. UTC

Печалби

BASF Cuts Outlook on Global Economic Uncertainty

11.07.2025 г., 16:08 ч. UTC

Пазарно говорене

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11.07.2025 г., 16:05 ч. UTC

Печалби

BASF Will Publish Half-Year Results on July 30

11.07.2025 г., 16:04 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

11.07.2025 г., 16:04 ч. UTC

Пазарно говорене

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11.07.2025 г., 16:03 ч. UTC

Печалби

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11.07.2025 г., 16:02 ч. UTC

Печалби

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11.07.2025 г., 16:01 ч. UTC

Печалби

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11.07.2025 г., 16:00 ч. UTC

Печалби

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11.07.2025 г., 15:59 ч. UTC

Печалби

BASF Cuts 2025 Earnings View

11.07.2025 г., 15:58 ч. UTC

Печалби

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11.07.2025 г., 15:57 ч. UTC

Печалби

BASF 2Q EBIT Before Special Items EUR810M

11.07.2025 г., 15:54 ч. UTC

Печалби

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11.07.2025 г., 15:54 ч. UTC

Печалби

BASF 2Q Sales Fell 2.1% on Year

11.07.2025 г., 15:53 ч. UTC

Печалби

BASF 2Q Sales EUR15.77B

11.07.2025 г., 15:52 ч. UTC

Печалби

BASF: This Was in Line With Consensus Estimates

11.07.2025 г., 15:52 ч. UTC

Печалби

BASF 2Q Ebitda Before Special Items EUR1.77B

11.07.2025 г., 15:49 ч. UTC

Печалби

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11.07.2025 г., 15:41 ч. UTC

Пазарно говорене

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Insulet Corp Прогноза

Ценова цел

By TipRanks

14.23% нагоре

12-месечна прогноза

Среден 339.79 USD 14.23%

Висок 380 USD

Нисък 266 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за Insulet Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

21 ratings

Купи

Задържане

Продай

Според 21 анализатори, дали борсови рейтинги на Insulet Corp през последните 3 месеца.

Техническа оценка

By Trading Central

252.29 / 259.38Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

2 / 376 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Insulet Corp

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.